Title:
IL-10 MONOMER FUSION PROTEIN AND USE THEREOF
Document Type and Number:
WIPO Patent Application WO/2023/078245
Kind Code:
A1
Abstract:
Provided are an IL-10 monomer fusion protein and a use thereof, which relate to the field of biomedicine. The fusion protein comprises an antibody and an IL-10 monomer. The fusion protein of the present invention has a relatively strong targeting property, so that the safety thereof is remarkably improved. Moreover, the protein may effectively treat or prevent various tumors or inflammatory diseases.
Inventors:
LU DI (CN)
HUO YONGTING (CN)
ZHANG YIBO (CN)
YAN JIAQING (CN)
HUO YONGTING (CN)
ZHANG YIBO (CN)
YAN JIAQING (CN)
Application Number:
PCT/CN2022/128998
Publication Date:
May 11, 2023
Filing Date:
November 01, 2022
Export Citation:
Assignee:
GUANGDONG FEIPENG PHARMACEUTICAL CO LTD (CN)
International Classes:
C07K14/54; A61K39/395; C07K16/18; C07K19/00; C12N15/26
Foreign References:
| CN104540848A | 2015-04-22 | |||
| CN104540848A | 2015-04-22 | |||
| CN106061997A | 2016-10-26 | |||
| CN103649114A | 2014-03-19 | |||
| US20170158747A1 | 2017-06-08 | |||
| US20170158747A1 | 2017-06-08 |
Other References:
高瑞等 (GAO, RUI ET AL.): "抗体- 细胞因子融合蛋白治疗肿瘤的前景 (Prospect of Antibody-Cytokine Fusion Proteins for the Therapy of Cancer)", 药物生物技术 (PHARMACEUTICAL BIOTECHNOLOGY), vol. 27, no. 2, 31 December 2020 (2020-12-31), XP093032875, DOI: 10.19526/j.cnki.1005-8915.20200219
MURER, P. ET AL.: "Antibody-cytokine Fusion Proteins: A Novel Class of Biopharmaceuticals for the Therapy of Cancer and of Chronic Inflammation", NEW BIOTECHNOLOGY, vol. 52, 13 April 2019 (2019-04-13), pages 42 - 53, XP085726498, DOI: 10.1016/j.nbt.2019.04.002
MURER, P. ET AL.: "Antibody-cytokine Fusion Proteins: A Novel Class of Biopharmaceuticals for the Therapy of Cancer and of Chronic Inflammation", NEW BIOTECHNOLOGY, vol. 52, 13 April 2019 (2019-04-13), pages 42 - 53, XP085726498, DOI: 10.1016/j.nbt.2019.04.002
Attorney, Agent or Firm:
TSINGYIHUA INTELLECTUAL PROPERTY LLC (CN)
Download PDF: